First Foundation Advisors Alnylam Pharmaceuticals, Inc. Transaction History

First Foundation Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $96,661 - $125,722	-521 Reduced 27.45%	1,377 $327,000
Q3 2022 Nov 10, 2022	SELL	$138.54 - $232.0 $217,230 - $363,776	-1,568 Reduced 45.24%	1,898 $380,000
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $1.03 Million - $1.45 Million	-8,568 Reduced 71.2%	3,466 $506,000
Q1 2022 May 05, 2022	SELL	$127.18 - $173.91 $309,047 - $422,601	-2,430 Reduced 16.8%	12,034 $1.97 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $95,736 - $125,574	600 Added 4.33%	14,464 $2.45 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $175,691 - $215,000	1,035 Added 8.07%	13,864 $2.62 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $148,567 - $204,307	1,155 Added 9.89%	12,829 $2.18 Million
Q1 2021 May 18, 2021	BUY	$126.83 - $175.69 $1.48 Million - $2.05 Million	11,674 New	11,674 $1.65 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

Stay updated on First Foundation Advisors with notifications on news.